Combination therapy with irinotecan and protein kinase C inhibitors in malignant glioma

Cancer

Volumn 97, Issue 9 SUPPL., 2003, Pages 2363-2373

  Chen, Thomas C ^a   Su, Susan ^a   Fry, David ^b   Liebes, Leonard ^b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b NEW YORK UNIVERSITY   (United States)

Author keywords

Apoptosis; Irinotecan (CPT 11); Protein kinase C (PKC) inhibition; SN 38; Tumor carboxylesterase

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; CALPHOSTIN C; CARBOXYLESTERASE; HYPERICIN; IRINOTECAN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE C; PROTEIN KINASE C INHIBITOR; STAUROSPORINE; TAMOXIFEN; TUMOR CARBOXYLESTERASE; UNCLASSIFIED DRUG;

APOPTOSIS; CANCER CELL CULTURE; CELL PROLIFERATION; CELL STRUCTURE; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG MIXTURE; DRUG POTENTIATION; DRUG SENSITIVITY; ENZYME INHIBITION; GENE INDUCTION; GLIOBLASTOMA; GLIOMA CELL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; NICK END LABELING; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING;

EID: 0037403698     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11307     Document Type: Conference Paper

References (35)

1. Agirisi A, Murren JR. Clinical use of the camptothecins at year 2000. In: Principles and practices of oncology updates. Philadelphia: Lippincott-Raven, 2000;14:1-15.
2. Nakatsu S, Kondo S, Kondo Y, et al. Induction of apoptosis in multi-drug resistant (MDR) human glioblastoma cells by SN-38, a metabolite of the camptothecin derivative CPT-11. Cancer Chemother Pharmacol. 1997;39:417-423.
3. Hare CB, Eliori GB, Houghton PJ, et al. Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against pediatric and adult central nervous system tumor xenografts. Cancer Chemother Pharmacol. 1997;39:187-191.
4. Coggins CA, Elion GB, Houghton PJ, et al. Enhancement of irinotecan (CPT-11) activity against central nervous system tumor xenografts by alkylating agents. Cancer Chemother Pharmacol. 1998;41:485-490.
5. Cloughsey TF, Filke E, Nelson G, et al. Irinotecan treatment for recurrent malignant glioma using an every 3-week regimen. Am J Clin Oncol. 2002;25:204-208.
6. Friedman HS, Petros WP, Friedman AH, et al. Irinotecan therapy in adults with recurrent or progressive malignant glioma. J Clin Oncol. 1999;17:1516-1525.
7. Cusack JC Jr., Liu R, Houston M, et al. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-KB inhibition. Cancer Res. 2001;61:3535-3540.
8. Couldwell WT, Hinton DR, Surnock AA, et al. Treatment of recurrent malignant gliomas with chronic oral high-dose tamoxifen. Clin Cancer Res. 1996;2:619-622.
9. Chang SM, Barker FG 2nd, Huhn SL, et al. High dose oral tamoxifen and subcutaneous alpha-2a for recurrent glioma. J Neurooncol. 1998;37:169-176.
10. , Mastronardi L, Puzzilli F, Couldwell WT, Farah JO, Lunardi P. Tamoxifen and carboplatin combinational treatment of high-grade gliomas. Results of a clinical trial on newly diagnosed patients. J Neurooncol. 1998;38:59-68.
11. Brandes AA, Emani M, Turazzi S, et al. Procarbazine and high-dose tamoxifen as a second-line regimen in recurrent high-grade gliomas: a phase II study. J Clin Oncol. 1999;17:645-650.
12. da Rocha AB, Mans DR, Bernard EA, et al. Tamoxifen inhibits particulate-associated protein kinase C activity, and sensitises cultured human glioblastoma cells not to etoposide, but to γ-radiation and BCNU. Eur J Cancer. 1999;35:833-839.
13. Cheng AL, Chuang SE, Fine RL, et al. Inhibition of the membrane translocation and activation of protein kinase C, and potentiation of doxorubicin-induced apoptosis of hepatocellular carcinoma cells by tamoxifen. Biochem Pharmacol. 1998;55:523-531.
14. Gunimeda U, Chen ZH, Gopalakrishna R. Tamoxifen modulates protein kinase C via oxidative stress in estrogen receptor-negative breast cancer cells. J Biol Chem. 1996;271:13504-13514.
15. Chen TC, Hinton DR, Zidovetzki R, Hofman FM. Upregulation of the cAMP/PKA pathway inhibits proliferation, induces differentiation, and leads to apoptosis in malignant gliomas. Lab Invest. 1998;78:165-174.
16. Guichard S, Terret C, Hennebelle I, et al. CPT-11 converting carboxylesterase and topoisomerase I activities in tumour and normal colon and liver tissues. Br J Cancer. 1999;80:364-370.
17. O'Meara AT, Sevin B-U. In vitro sensitivity of fresh ovarian carcinoma specimens to CPT-11 (irinotecan). Gynecol Oncol. 1999;72:143-147.
18. Kaiser MG, Parsa AT, Fine RL, Hall JS, Chakrabarti I, Bruce JN. Tissue distribution and antitumor activity of topotecan delivered by intracerebral clysis in a rat glioma model. Neurosurgery. 2000;47:1391-1399.
19. Debinski W. Local treatment of brain tumors with targeted chimeric cytotoxic proteins. Cancer Invest. 2002;20:801-809.
20. Voigt W, Matsui S, Yin MB, Burhans WC, Minderman H, Rustum YM. Topoisomerase-I inhibitor SN-38 can induce DNA damage and chromosomal aberrations independent from DNA synthesis. Anticancer Res. 1998;18:3499-3505.
21. Liebes L, Potmesil M, Kim T, et al. Pharmacodynamics of topoisomerase I inhibition: Western blot determination of topoisomerase I and cleavable complex in patients with upper gastrointestinal malignancies treated with topotecan. Clin Cancer Res. 1998;4:545-557.
22. Morton CL, Wadkins RM, Danks MK, Potter PM. The anticancer prodrug CPT-11 is a potent inhibitor of acetylcholinesterase but is rapidly catalyzed to SN-38 by butyrlcholinesterase. Cancer Res. 1999;59:1458-1463.
23. Iyer L, King CD, Whitington PF, et al. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest. 1998;101:847-854.
24. Gupta E, Mick R, Ramirez J, et al. Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients. J Clin Oncol. 1997;15:1502-1510.
25. Zellner A, Fetell MR, Bruce JN, De Vivo DC, O'Driscoll KR. Disparity in expression of protein kinase C α in human glioma versus glioma-derived primary cell lines: therapeutic implications. Clin Cancer Res. 1998;4:1797-1802.
26. Benzil D, Finkelstein L, Epstein SD, Finch PW. Expression pattern of a-protein kinase C isozymes in human brain tumors. Cancer Res. 1992;15;52:2951-2956.
27. Blackburn RV, Galoforo SS, Berns CM, Motwani NM, Corry PM, Lee YJ. Differential induction of cell death in human glioma cell lines by sodium nitroprusside. Cancer. 1998;82: 1137-1145.
28. Ikemoto H, Tani E, Matsumoto T, Nakano A, Furuyama J. Apoptosis of human glioma cells in response to calphositin C, a specific protein kinase C inhibitor. J Neurosurg. 1995;83:1008-1016.
29. Onishi Y, Oguro M, Kizaki H. 4-Piperidinopiperidine-resistant lymphoma cells were resistant to dexamethasone- and A23187-induced apoptosis. Cancer Lett. 1998;127:147-153.
30. Hara A, Hirose Y, Yoshimi N, Tanaka T, Mori H. Expression of bax and bcl-2 proteins, regulators of programmed cell death, in human brain tumors. Neurol Res. 1997;19:623-628.
31. Kanavaros P, Stefanaki K, Valassiadou K, et al. Expression of p53, p21/waf, bcl-2, bax, Rb and Ki67 proteins in colorectal adenocarcinomas. Med Oncol. 1999;16:23-30.
32. Rabinowicz AL, Hinton DR, Dyck P, Couldwell WT. High-dose tamoxifen in treatment of brain tumors: interaction with antiepileptic drugs. Epilepsia. 1995;36:513-515.
33. Lara PN Jr., Gandara DR, Wurz GT, et al. High dose toremifene as a cisplatin modulator in metastatic non-small cell lung cancer: targeted plasma levels are achievable clinically. Cancer Chemother Pharmacol. 1998;42:504-508.
34. Sausville EA, Arbuck SG, Messmann R, et al. Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms. J Clin Oncol. 2001;19:2319-2333.
35. Koutcher JA, Motwani M, Zakian KL, et al. The in vivo effect of bryostatin-1 on paclitaxel induced tumor growth, mitotic entry, and blood flow. Clin Cancer Res. 2000;6:1498-1507.